龍佰集團(002601.SZ):近期取得13項發明專利證書
格隆匯9月7日丨龍佰集團(002601.SZ)公佈,近期,公司及子公司河南佰利聯新材料有限公司(“新材料公司”)、龍佰四川鈦業有限公司(“龍佰四川”)收到國家知識產權局頒發的13項發明專利證書。此次新增的發明專利如下:


注:以上發明專利的專利權有效期自申請日起算。
上述發明專利的取得不會對公司生產經營產生重大影響,但在一定程度上有利於公司保護自主知識產權,防止侵權事件發生,掌握市場競爭主動權,形成持續自主創新機制和能力,保持技術和產品的領先和競爭優勢,提高公司品牌和市場影響力,進一步提升公司的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.